Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL30467775

COc1cc(OC(F)(F)F)c(B2OC(C)(C)C(C)(C)O2)cc1-c1ccc2c(N)nnc(C)c2c1.O=C(O)C(F)(F)F

nearest known ligand 0.32

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
F2 P00734 2/20 0.32
F11 P03951 2/20 0.32
PRSS1 P07477 2/20 0.32
PRSS2 P07478 2/20 0.32
PRSS3 P35030 2/20 0.32
SCN9A Q15858 1/20 0.31
CTSA P10619 1/20 0.31
LIPE Q05469 2/20 0.31
ABL1 P00519 1/20 0.31
PDGFRB P09619 1/20 0.30
KDR P35968 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24252781 0.94 SCN9A (0.33) SCN9A
Trifluoroacetic Acid SCHEMBL30467602 0.91 F2 (0.34) F2F11PRSS1PRSS2PRSS3
Trifluoroacetic Acid SCHEMBL30467592 0.85 F2 (0.40) F2F11PRSS1PRSS2PRSS3
SCHEMBL24252330 0.81 DHFR (0.32)
Trifluoroacetic Acid SCHEMBL30467673 0.79 F2 (0.38) F2F11PRSS1PRSS2PRSS3
SCHEMBL24252657 0.76 SCN9A (0.35) SCN9AABL1
SCHEMBL30453116 0.76 SCN9A (0.35) SCN9AABL1
Trifluoroacetic Acid SCHEMBL30467711 0.76 F2 (0.35) F2F11PRSS1PRSS2PRSS3
SCHEMBL24252272 0.75 CSF1R (0.40) PDGFRBKDR
Trifluoroacetic Acid SCHEMBL30467727 0.74 F2 (0.35) F2F11PRSS1PRSS2PRSS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 F2 125/4885F11 117/4885PRSS1 193/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 F2 125/4885F11 117/4885PRSS1 193/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH F2 1425/4885F11 195/4885PRSS1 2762/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 F2 406/4885F11 177/4885PRSS1 1554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.